MicroRNA-101a enhances trabecular bone accrual in male mice

Dudakovic, Amel; Jerez, Sofia; Deosthale, Padmini J.; Denbeigh, Janet M.; Paradise, Christopher R.; Gluscevic, Martina; Zan, Pengfei; Begun, Dana L.; Camilleri, Emily T.; Pichurin, Oksana; Khani, Farzaneh; Thaler, Roman; Lian, Jane B.; Stein, Gary S.; Westendorf, Jennifer J.; Plotkin, Lilian I.; van Wijnen, Andre J.

doi:10.1038/s41598-022-17579-0

Download PDF

Article
Open access
Published: 03 August 2022

MicroRNA-101a enhances trabecular bone accrual in male mice

Amel Dudakovic^1,2,
Sofia Jerez¹,
Padmini J. Deosthale³,
Janet M. Denbeigh¹,
Christopher R. Paradise^4,5,
Martina Gluscevic^1,5,
Pengfei Zan^1,6,7,
Dana L. Begun¹,
Emily T. Camilleri¹,
Oksana Pichurin¹,
Farzaneh Khani¹,
Roman Thaler¹,
Jane B. Lian⁸,
Gary S. Stein⁸,
Jennifer J. Westendorf^1,2,
Lilian I. Plotkin^3,9,10 &
…
Andre J. van Wijnen⁸

Scientific Reports volume 12, Article number: 13361 (2022) Cite this article

996 Accesses
4 Citations
1 Altmetric
Metrics details

Subjects

Abstract

High-throughput microRNA sequencing was performed during differentiation of MC3T3-E1 osteoblasts to develop working hypotheses for specific microRNAs that control osteogenesis. The expression data show that miR-101a, which targets the mRNAs for the epigenetic enzyme Ezh2 and many other proteins, is highly upregulated during osteoblast differentiation and robustly expressed in mouse calvaria. Transient elevation of miR-101a suppresses Ezh2 levels, reduces tri-methylation of lysine 27 in histone 3 (H3K27me3; a heterochromatic mark catalyzed by Ezh2), and accelerates mineralization of MC3T3-E1 osteoblasts. We also examined skeletal phenotypes of an inducible miR-101a transgene under direct control of doxycycline administration. Experimental controls and mir-101a over-expressing mice were exposed to doxycycline in utero and postnatally (up to 8 weeks of age) to maximize penetrance of skeletal phenotypes. Male mice that over-express miR-101a have increased total body weight and longer femora. MicroCT analysis indicate that these mice have increased trabecular bone volume fraction, trabecular number and trabecular thickness with reduced trabecular spacing as compared to controls. Histomorphometric analysis demonstrates a significant reduction in osteoid volume to bone volume and osteoid surface to bone surface. Remarkably, while female mice also exhibit a significant increase in bone length, no significant changes were noted by microCT (trabecular bone parameters) and histomorphometry (osteoid parameters). Hence, miR-101a upregulation during osteoblast maturation and the concomitant reduction in Ezh2 mediated H3K27me3 levels may contribute to the enhanced trabecular bone parameters in male mice. However, the sex-specific effect of miR-101a indicates that more intricate epigenetic mechanisms mediate physiological control of bone formation and homeostasis.

MiR-1224-5p modulates osteogenesis by coordinating osteoblast/osteoclast differentiation via the Rap1 signaling target ADCY2

Article Open access 13 July 2022

Inhibition of miR338 rescues cleidocranial dysplasia in Runx2 mutant mice partially via the Hif1a-Vegfa axis

Article Open access 04 January 2023

LncMIR181A1HG is a novel chromatin-bound epigenetic suppressor of early stage osteogenic lineage commitment

Article Open access 11 May 2022

Introduction

Osteogenesis is mediated by the dynamic activation and suppression of gene expression programs in osteoblasts that produce a collagenous mineralized matrix^{1,2,3,4,5,6,7,8,9}. The production and deposition of bone-specific extracellular matrix proteins is controlled by epigenetic mechanisms that modulate the accessibility of transcription factors to gene loci in chromatin^1,10. Genetic studies have established that many distinct epigenetic regulators contribute to skeletal development and bone formation in vivo, including enzymes and proteins that control DNA methylation, as well as histone acetylation and methylation^10,11,12. Beyond chromatin-related mechanisms, bone-specific gene expression is also controlled by post-transcriptional epigenetic events mediated by microRNAs (miRNAs) that regulate stability and/or translation of osteoblast-related mRNAs^5,13.

The importance of miRNAs in control of bone formation and homeostasis in vivo is evidenced by mouse models incapable of producing mature miRNAs due to conditional knock-out of the endonuclease Dicer¹⁴. It has been challenging to investigate the functional roles for specific miRNA loci because of redundancy between miRNA isoforms that are encoded by multiple related miRNA gene loci or nearly identical gene copies¹³. The latter has been addressed in part by strategies that target multiple miRNAs at once using compound gene knockouts or decoys^15,16. Many studies have focused on the identification of miRNAs that regulate expression of important signaling pathways and transcription factors in cell culture models for osteoblastogenesis^{17,18,19,20,21,22,23,24,25,26}. Among the latter studies, several related themes have emerged. First, principal gene regulators that control osteoblast differentiation are targeted by more than one miRNA^21,27. For example, the bone master regulator Runx2 is controlled by more than ten distinct miRNAs that collectively may control lineage commitment in mesenchymal progenitor cells^19,21,27. Other studies have shown that miRNA gene clusters, which encode distinct sets of miRNAs with different targets, may collectively regulate signaling pathways required for osteogenesis^22,23. These studies reflect the complexity of miRNA mediated regulatory networks in which each miRNA has a large number of potential mRNA targets and that each mRNA target can interact with many distinct miRNAs. This molecular diversity permits different levels of regulatory interdependence between signaling pathways and transcription factors and supports negative and positive feedback loops that can either stimulate or attenuate cellular processes like osteoblastogenesis^5,13,28.

In this study, we examined miRNAs that are upregulated during calvarial osteoblast differentiation. Among these miRNAs we detected miR-101a, a microRNA that has multiple targets including the epigenetic regulator Ezh2^29,30,31,32. The latter epigenetic enzyme suppresses osteoblast differentiation^{11,33,34,35,36} as well as supports lineage progression and self-renewal of mesenchymal stromal cells^37,38,39,40. To assess whether this nexus between mir-101a and Ezh2 impacts bone formation, we performed in vivo gain of function studies with miR-101a using an inducible transgenic approach. Here we show that miR-101a has sex-dependent post-natal effects on trabecular bone parameters.

Results

Changes in miRNA expression during differentiation of MC3T3 pre-osteoblasts

To assess changes in the non-coding transcriptome of miRNAs during osteoblastogenesis, microRNA-sequencing (miRNA-seq) was performed using total RNA isolated during differentiation of MC3T3 E1 subclone 4 (referred to here as MC3T3) pre-osteoblasts. Because the MC3T3 cell line was originally derived from mouse calvaria, total RNA samples from frontal and parietal bones derived from neo-natal (i.e., 2–3 day old pups) female mice were evaluated in parallel for in vivo relevance. Based on our previous RNA-seq assessment³⁵ (data not shown), MC3T3 E1 subclone 4 cells express genes located on the Y chromosome (e.g., Kdm5d and Uty), suggesting that these cells are derived from male mice. Of the 1,418 miRNAs detected by our sequencing platform, 168 miRNAs exhibit very robust expression with counts per million (CPM) values exceeding one hundred (CPM > 100) when averaged across five MC3T3 differentiation time points (days 0, 6, 10, 17, and 24) (Suppl Table 1). While some miRNAs are differentially expressed, expression of other miRNAs remains relatively constant during the MC3T3 differentiation time course. Unlike miRNA-seq analysis using calvaria that were sequenced with bones from three animals (biological triplicates), each individual time point obtained during the MC3T3 time course was analyzed as a single miRNA-seq run of a pooled biological triplicate sample because inter-sample variation for established cell lines is remarkably minor in our experience. Although no statistical analysis was possible on individual two-way sample comparisons for MC3T3 cells during the time course, the consistency of these data is reflected by matrix analysis (hierarchical clustering in heatmap) and curve fitting (time course graph) (see below).

Hierarchical clustering analysis of robustly expressed miRNAs reveals separation between differentiating MC3T3 cells and mouse calvaria (Fig. 1A). Interestingly, these analyses also reveal three temporal sub-clusters within MC3T3: undifferentiated (day 0), early differentiation states (days 6 and 10), and late differentiation states (days 17 and 24). To identify robustly expressed miRNAs that may regulate osteogenic differentiation, additional analysis focused on the identification of miRNAs that are differentially expressed during osteoblast differentiation of MC3T3 cells. Of the robustly expressed miRNAs (n = 168), 36 miRNAs are up-regulated (Fig. 1B) and three are down-regulated (Fig. 1C) across all four differentiation time points when compared to undifferentiated MC3T3 cells (fold change (FC) > 2) (Suppl Table 2). To narrow the search of miRNAs that may regulate osteogenesis, miRNAs induced on average above 1,000 CPM in both MC3T3 cells (in vitro model) and primary mouse calvaria (in vivo relevance) (Suppl Table 2 and Fig. 1D) were selected for further analysis. Of these 13 miRNAs, we considered miR-101a-3p of greatest interest, because it was shown to suppress Ezh2^29,41, which is an epigenetic enzyme that mediates trimethylation of lysine 27 on histone 3 (H3K27me3). Our previous work established that repression of Ezh2 promotes osteogenic differentiation in vitro, stimulates bone formation in vivo, and protects against bone loss due to estrogen depletion^33,35,37,42. Therefore, the present studies address the role of miR-101a on osteogenesis in vitro and bone formation in vivo.

miR-101 modulates Ezh2 activity and enhances osteogenic differentiation of MC3T3 cells

We first sought to determine whether miR-101 over-expression can modulate Ezh2, H3K27 methylation, and osteogenic differentiation in mouse derived MC3T3 pre-osteoblasts (Fig. 2A). One day after transfection, Cy3 (negative control pre-miR) was detected by fluorescence microscopy (Fig. 2B). Live and dead cell staining revealed similar viability in Cy3 and miR-101a-3p transfected MC3T3 cells (Fig. 2C). Western blotting analysis indicates a reduction in Ezh2 protein and H3K27me3 levels three and five days after transfection of miR-101a-3p in MC3T3 cells grown in either basal or differentiation medium (Fig. 2D). The levels of the cytoplasmic protein β-actin (gene symbol ACTB) and total levels of the nuclear protein histone 3 (H3) are indistinguishable between Cy3 and miR-101a-3p transfected cells indicating that the gel lanes were loaded equally. Our results validates previous findings for the miR-101a-3p/Ezh2 nexus initially observed in non-bone related cancer cell types^29,41, osteosarcoma⁴³ and during osteogenic differentiation of mesenchymal stromal cells⁴⁴, and extends these findings to osteoblastic MC3T3 cells.

To assess the impact of miR-101a on osteogenesis, MC3T3 cells were differentiated upon transfection with Cy3, miR-101a-3p or miR-27b, which was also up-regulated during osteogenic differentiation (Fig. 1) and previously shown to stimulate osteoblast differentiation^45,46. Over-expression of either miR-101a-3p or miR-27b enhances osteogenic differentiation of MC3T3 pre-osteoblasts as shown by alizarin red staining (Fig. 2E,F). Taken together, our evidence shows that miR-101 suppresses Ezh2 and H3K27me3 levels and enhances osteogenic commitment of MC3T3 pre-osteoblasts. The finding that miR-101 regulation of Ezh2 and osteogenesis in vitro is sufficiently robust in different biological contexts provides a solid experimental foundation for in vivo studies on the role miR-101 in bone formation.

Establishing miR-101 over-expression in bone tissue

We evaluated the role of miR-101a on bone formation by establishing a transgenic mouse colony through mouse embryonic stem cells from the National Cancer Institute⁴⁷. In this transgenic mouse model, expression of miR-101a is achieved using a gene cassette that was inserted in a transcriptionally permissive region downstream of the 3’UTR of the Col1a1 gene (Suppl Fig. 1). This cassette contains a tetracycline (tet)-responsive element (TRE-tight; Tet Operator/TetO) upstream from a green fluorescent protein (GFP) with a 3′ untranslated region containing the sequences for miR101a (i.e., embedded within the pre-miRNA scaffold for human miR-30). This primary transgene is activated by a secondary transgene expressing a doxycycline-inducible tet-transactivator (tTA) from the Rosa26 locus (Rosa26/tTA). Three-week-old mice heterozygous for both the mir-101a over-expression cassette and the Rosa26/tTA locus were maintained on a regular doxycycline-rich diet for five weeks to assess miR-101a and GFP expression (Fig. 3). In a RT-qPCR screen of eight tissues, GFP expression is evident in skin, spleen, and bone (femora) in eight-week-old female mice on doxycycline diet (Fig. 3A). Because GFP is not normally expressed in mice, the GFP/miR-101a transgene model should represent a zero-background system in the absence of doxycycline. Nevertheless, we detected low levels of GFP expression due to ‘leaky’ transcription from the TRE-tight promoter in tissues from mice maintained on a regular diet see (black bars in bone). Similar to GFP, mir-101a expression is enhanced by doxycycline administration in skin, spleen, and bone (Fig. 3B). Unlike GFP, miR-101a is also up-regulated in liver; because the transgene transcript encodes both RNAs, this finding may perhaps reflect the relative stabilities of small miRNAs versus longer mRNAs.

To confirm utility of this mouse model for examination of skeletal phenotype and for bone-related studies, expression of both miR-101a and GFP was also assessed in bones (femora) and two additional mesenchymal tissues (muscle and fat) from a larger cohort of male mice. GFP expression was significantly enhanced in the femora of male mice upon doxycycline-administration (Fig. 3D). As anticipated, mRNAs for Col1a1 and Sp7 (encoding the bone-specific transcription factor Osterix) are both expressed in bone, while Adipoq mRNA (encoding adiponectin) is enriched in fat. Interestingly, while Ezh2 mRNA is unchanged by the doxycycline diet, basal Ezh2 mRNA levels are higher in bone tissues when compared to muscle and fat. Similar to Ezh2, expression of the housekeeping gene Akt1 is not affected by doxycycline although its levels vary between mesenchymal tissues. Importantly, miR-101a levels are significantly up-regulated (5.5-fold) in femora of mice on doxycycline diet (Fig. 3C), but the levels of an independent miRNA, miR-218, are not affected. To determine if miR-101a over-expression is reversible in bone tissue, male mice were fed regular and/or doxycycline-supplemented diet (Fig. 4A). Like the initial cohorts (Fig. 3), a five-week doxycycline diet enhances expression of both miR-101a (Fig. 4B) and GFP (Fig. 4C) in eight-week-old male femora. Interestingly, replacement of doxycycline with regular diet (D > R) at six weeks abolishes expression of miR-101a and GFP levels but does not affect transcript levels of miR-181a and Akt1 (negative controls). In summary, while not tissue-specific, the GFP/miR-101a mouse model allows for inducible and reversible up-regulation of miR-101a in bone tissues with GFP expression as a useful reporter.

miR-101a over-expression stimulates bone formation in male mice

To assess the impact of miR-101a over-expression on bone formation, two control groups and the experimental group of mice were placed on doxycycline diet from inception until sacrifice^47,48,49. The two control groups are: R26 control (heterozygous for tTA/Rosa26 locus) and miR-101a control (heterozygous for mir-101a over-expression cassette). The experimental group is referred to as R26/101a or miR-101a over-expressing mice (heterozygous for both the GFP/mir-101a over-expression cassette and tTA/Rosa26 locus). Together these groups adequately account for the effects of miR-101a overexpression and doxycycline exposure, which can modulate bone formation^50,51,52.

To assess GFP and mir-101a levels, RT-qPCR analysis was performed on femoral RNA derived from the three male cohort groups. When compared to both control groups, GFP mRNA levels are significantly enhanced in the miR-101a over-expressing mice (Fig. 5A). The levels of Eef1a1, a stably expressed housekeeping gene, remain constant among the three mouse groups. Similar to GFP mRNA levels, miR-101-5p is up-regulated in bone tissues of miR-101a over-expressing mice as expected (Fig. 5B). For comparison, the levels of miR-191-5p are constant across the three mouse groups. Interestingly, expression analysis reveals a difference in the levels of miR-101-5p (Fig. 5B) and GFP mRNA (Fig. 5C) between the two control groups; as noted above, detection of any mRNA may be less sensitive than any miRNA because the latter tend to be more stable. Thus, while miR-101a is robustly induced in the miR-101a over-expressing mice, it should also be noted that miR-101a is also elevated in the 101a control group when compared to the R26 control group, suggesting leaky transcription from the miR-101a over-expression cassette.

Overexpression of miR101a in male mice increases femoral length with a commensurate increase in body weight when compared to both R26 and miR-101a control mice (Fig. 6A,B). Female mice exhibit a similar overall phenotype with miR-101a dependent changes in weight and femoral length phenotype, except that the body weight of female miR-101a over-expressing mice was only statistically different from miR-101a controls, but not from R26 controls (Fig. 7A,B). Skeletal analyses using μCT reveals increases in trabecular bone volume fraction, trabecular number, and trabecular thickness, while a decrease in trabecular spacing and structure model index is observed in male miR-101a over-expressing mice when compared to R26 control mice (Fig. 6C–G). The miR-101a control mice are similar to R26 control mice (except for increased trabecular thickness), but the μCT parameters are not significantly different between miR-101a controls and miR-101a over-expressing mice. Of interest, when assessing body weight, femur length, and trabecular bone parameters, the phenotype of miR-101a control mice is consistently between R26 controls and miR-101a over-expressing mice. The latter is consistent with ‘leaky’ transcription of the transgenic cassette as noted above (see Figs. 3 and 5). Thus, the elevated expression of the miR-101a transgene in the miR-101a controls may explain the lack of statistical difference between miR-101a controls and miR-101a over-expressing male mice (see Fig. 5). In contrast to male mice, no differences in trabecular bone parameters measured by µCT are observed among the three groups in female mice (Fig. 7C–G). Further, overexpression of miR-101a did not alter cortical bone geometry in the femoral mid-diaphysis for either male (Fig. 6H) or female (Fig. 7H) mice. Thus, μCT results collectively indicate that inducible transgenic expression of miR-101a during post-natal skeletal development alters bone parameters.

Because miR-101a control is leaky and permits a limited level of miR-101a expression even in the absence of tetracycline-dependent transcriptional activator (tTA), histomorphometric analyses were performed on femora derived from R26 control and miR-101a overexpressing mice (Suppl Fig. 2). Static histomorphometric analyses performed on cancellous bone of the distal femur showed that osteoid volume and surface covered by osteoid are significantly decreased in bones from male mice, whereas the number and surface of osteoblasts do not vary, resulting in a significant decrease in the corrected osteoid surface per osteoblast in miR-101a over-expressing male mice when compared to R26 control male mice (Fig. 8). On the other hand, osteoclast number and surface, as well as eroded surface and osteocyte density are similar between R26 control and miR-101a over-expressing male mice. However, miR-101a over-expression does not alter osteoid or osteoblastic parameters but results in a small but significant decrease in osteocyte density, and in osteoclast and eroded surface in cancellous bone of distal femurs when compared to R26 control in female mice (Fig. 9). These results do not exclude the possibility that increased bone mass due to decreased bone resorption could still become evident at a later age, but this prediction has not yet been tested. Regardless of the local changes in bone geometry and cell number/surface that reflect the dynamics of bone homeostasis, the overall remodeling state is not altered by miR-101a overexpression, as evidenced by lack of changes in circulating levels of the bone formation marker P1NP (i.e., procollagen type I N-terminal propeptide) and the resorption marker CTX (i.e., cross-linked C-telopeptide of type I collagen) in either male or female mice (Fig. 10). We cannot rule out the possibility that an imbalance favoring bone formation occurred at an earlier age (or during development), and that the animals reached a new steady state in which formation and resorption are similar to those of control mice at the time of euthanasia. Nevertheless, these data demonstrate that persistent miR-101a induction (from inception to 8 weeks) stimulates trabecular bone formation in male mice.

Trabecular bone formation is refractory to miR-101a induction post-weaning in male mice

To assess the impact of miR-101a on bone formation after weaning, three-week-old male mice from R26 control and miR-101 over-expressing cohorts were placed on a doxycycline rich diet until early skeletal maturity (twelve weeks). No differences were observed in body weight (Fig. 11A) and femora length (Fig. 11B) between control and miR-101a over-expressing mice. A small but significant reduction in trabecular number (Fig. 11D) and an increase in trabecular spacing (Fig. 11F) are apparent, but the trabecular bone volume fraction (Fig. 11C), trabecular thickness (Fig. 11E), trabecular structural model index (Fig. 11G), and cortical thickness (Fig. 11H) are similar between R26 control and miR-101a over-expressing mice. Taken together, inducible over-expression of miR-101a after weaning is not sufficient to enhance bone formation in male mice.

Discussion

Alterations in the expression of epigenetic molecules, including miRNAs and epigenetic enzymes, during mesenchymal progenitor commitment and osteoblast lineage progression can reveal epigenetic events that maintain progenitors in an undifferentiated state or may stimulate their commitment into more differentiated states. Our current approach utilized microRNA-sequencing to identify miRNAs that are differentially expressed in MC3T3 cells and may regulate osteogenic differentiation and bone formation. Results from our microRNA-Seq expression screen revealed numerous differentially expressed miRNAs during osteogenic differentiation of MC3T3 cells. Our strategy prioritized miRNAs that are expressed in calvaria and robustly up-regulated during osteoblast differentiation. Of the thirteen miRNAs that met both of these criteria, miR-101a is a non-coding RNA based suppressor that is known to target Ezh2 mRNA and other mRNAs. Of these regulatory interactions, the miR-101a/Ezh2 nexus has been established in many different cancer cells^29,41,53, and may operate ubiquitously in many other cell types.

While previous studies have firmly established that Ezh2 is a key target for miR-101a in osteosarcoma⁴³ and during osteogenic differentiation of mesenchymal stromal cells³², functional miRNA/mRNA interactions operative in one cell type may not occur in other cell types. For example, our previous studies have revealed cell type-specific differences in the potency of miRNAs (e.g., miR-23a and miR30c) to control distinct osteogenic or chondrogenic transcription factors (i.e., Runx2 and Trps1)^21,27. In view of cell type specific miRNA effects, it is reassuring that our data formally demonstrate that miR-101a indeed controls Ezh2 levels in osteoblastic MC3T3 cells.

There are many predicted targets for miR-101a that may influence bone cell physiology. We focused our interpretations of the physiological function of miR-101a on Ezh2, because Ezh2 is a broad epigenetic suppressor of osteogenesis that may account for many of the biological effects mediated by miR-101a. The observation that miR-101a upregulation correlates with decreased Ezh2 expression during osteoblast differentiation is consistent with an expanding number of studies from our group and others on the role of Ezh2 as a mediator of mesenchymal stem cell maintenance and an epigenetic suppressor of osteogenic differentiation^{35,36,37,38,42,54,55,56,57,58,59,60,61,62,63}. These studies collectively revealed that Ezh2 suppresses osteogenic differentiation and inhibition of this epigenetic enzyme is bone-anabolic and osteo-protective. Mechanistically, loss of Ezh2 function may enhance osteogenic pathways, including PTH, WNT, and BMP signaling. The present work supports and refines this model by invoking the idea that these osteogenic pathways are controlled by the Ezh2/miR-101a nexus because (i) miR-101a is reciprocally regulated relative to Ezh2 and (ii) miR-101a gain-of-function reduces Ezh2 levels in MC3T3 osteoblasts. Similar to knock-down and knock-out strategies or small molecule inhibition for Ezh2 that have bone anabolic potential^35,37,63,64, miR-101a may thus provide a natural small non-coding RNA-based mechanism by which Ezh2 (and perhaps other suppressors of osteogenesis directly targeted by miR-101a) can be targeted in osteoblast progenitor cells to stimulate osteogenic differentiation and bone formation.

Support for the impact of miR-101a on Ezh2 and osteogenic differentiation is provided by results from studies in which miR-101a-3p was transiently over-expressed in MC3T3 cells. Similar to the initial studies on the effects of miR-101a on human EZH2 in cancer cells^29,41, over-expression of miR-101a-3p suppresses Ezh2 protein levels in mouse MC3T3 osteoblasts cells maintained in either basal or osteogenic medium. Importantly, our studies also reveal a robust suppression of the H3K27me3 heterochromatin mark that is catalyzed by Ezh2. This finding indicates that Ezh2 is indeed a major cellular target of miR-101a and that there is mechanistic interplay between translational suppression of the multiple putative mRNA targets of miR-101a and reversal of Ezh2 mediated transcriptional suppression. Biologically, miR-101a-3p over-expression enhances alizarin red staining of MC3T3 cell cultures. Our findings are further supported by previous studies by Wang and colleagues who demonstrated that miR-101a stimulates osteogenic commitment of human bone-marrow derived mesenchymal stromal cells⁵⁹. Similar to miR-101a-3p, over-expression of miR-27b, another highly up-regulated miRNA in differentiating MC3T3s, stimulates MC3T3 differentiation as demonstrated by enhanced alizarin red staining. The involvement of miR-27b on osteogenic differentiation has been previously established in human fetal osteoblasts and may involve modulation of WNT signaling. Together, the pro-osteogenic functions of miR-101a-3p and miR-27b may converge on WNT signaling by the targeting of Ezh2 to alleviate suppressive epigenetic marks^35,42,59 and targeting of WNT modulators (SFRP1)^45,46, respectively.

To assess the impact of miR-101a in bone formation in vivo, we generated mice from transgenic embryonic stem cells in which miR-101a and GFP are expressed under control of a tetracycline/doxycycline responsive element (TRE)⁴⁷ that is genomically incorporated into transcriptionally permissive locus immediately downstream from the Col1a1 gene. By design, the over-expression of miR-101a is inducible by the presence of tTA (expressed from the Rosa26 locus) and doxycycline in many tissues; expression of the miR-101a transgene is primarily limited by the physiological availability of the doxycycline in cells and tissues. Characterization of this transgenic doxycycline inducible TRE/GFP/miR-101a mouse model demonstrates that doxycycline administration induces miR-101a levels in bone tissues. The up-regulation is reversible as doxycycline removal restores miR-101a levels to endogenous levels. Our findings thus validate the use of this type of transgenic mouse model as a valuable tool for assessing the overall physiological function of miRNAs in bone and other tissues.

To our knowledge, this study provides the first evidence showing that enhancing miR-101a expression stimulates bone formation in vivo. However, one of the limitations of our study is the broad tissue distribution of miR-101a expression. We noted that beyond enhanced levels in bone, miR-101a levels are also elevated as fully expected in other tissues (e.g., skin, spleen, and liver). These findings thus confirm that induction of miRNAs from the doxycycline inducible transgene occurs in a range of tissues consistent with the original design of the mouse model. As has been noted previously, this transgenic miRNA expression model can in principle be further refined by expressing the doxycycline-response tTA protein from a stringently regulated tissue specific promoter⁴⁷. However, even if tissue specific expression was achieved, in vivo observations could still be confounded by the findings that miRNA levels can circulate in bodily fluids and may alter expression of targeted proteins at distal tissues^5,65,66,67. Another limitation of our study is that our analysis of skeletal phenotypes is restricted (e.g., static versus dynamic bone morphometry, as well as no analysis of bone resorption, bone repair, steroid hormone depletion, or metabolic disruption). Considering the current pleiotropic effects of the current miR-101a transgene model, these studies will be more informative with a more refined mouse model that specifically expresses miR-101a only in committed osteoblasts or osteocytes.

To assess the impact of miR-101a over-expression on bone formation, control and experimental mice were placed on doxycycline diet from inception until sacrifice (blood stream in utero, mother’s milk, and consumption of doxycycline diet)^47,48,49. We observe increases in overall body weight and bone length in miR-101a over-expressing male and female mice. However, enhanced trabecular bone formation as measured by µCT analysis is only observed in male, but not female mice. Other sex-specific differences included a reduction in osteoid-related parameters, which may stem from accelerated bone mineralization, in males while females exhibited a reduction in osteoclast related parameters. Interestingly, miR-101a over-expression after weaning (3 to 12 weeks) did not alter the weight and bone length. Minor changes in trabecular bone parameters are observed and may suggest an inhibitory role for miR-101a post-weaning as indicated by a reduction in trabecular number and increase trabecular spacing. Altogether, our in vivo studies reveal that enhanced miR-101a expression stimulates bone formation when up-regulated in utero, but these effects are no longer observed when miR-101a induction is induced after weaning. These findings suggest that there is a principal role for miR-101a in early stages of development and that miR-101a may accelerate bone growth during endochondral ossification to increase bone length in males and females, as well as trabecular bone formation in male mice. The physiological reasons for the sex-related and developmental-stage dependent differences in bone phenotypes remain speculative at present. The complexity of developmental, molecular, physiological, and genetic considerations precludes the design of definitive experiments that would address uncertainties in the interpretation at this time.

While miR-101 has many predicted mRNA targets beyond Ezh2, the relationship between Ezh2 and miR-101 appears to be quite critical for cell growth and differentiation. The miR-101 dependent inhibition of Ezh2 reflects the dynamic and intricate interdependence between two distinct epigenetic regulatory events involving miR-101a suppressed translation (non-genomic) and Ezh2 suppressed transcription (epigenomic). Earlier studies by Varambally and colleagues revealed that expression of Ezh2 is enhanced upon genomic loss of miR-101²⁹. Consistent with our studies showing that Ezh2 is suppressed during osteogenic differentiation^35,37,42, our present study and the work by Wang and colleagues³² demonstrate that Ezh2 is a miR-101 target in differentiating MSCs and committed pre-osteoblasts. Thus, miR-101 may enhance osteogenic differentiation by suppressing the expression and activity of Ezh2, perhaps in parallel with physiological bone stimulatory effects of miR-101a on other mRNA targets and in distinct bone-related cell types (e.g., MSCs, osteoblasts, osteocytes, and osteoclasts). In support of our findings showing enhanced bone formation upon miR-101 induction, miR-101 over-expression in human MSCs enhances new bone formation in a mouse calvarial defect model³². Further corroborated by the work of Huang and colleagues⁵⁹, a model has emerged in which miR-101 and Ezh2 form a reciprocal negative feedback loop to regulate and fine-tune their expression levels and activities.

In conclusion, our present work and previous studies collectively demonstrate that miR-101 promotes osteogenic differentiation and bone formation in vivo. While the functional role of miR-101 in osteogenesis is intricately intertwined with Ezh2 levels, future studies may provide insights into Ezh2-independent functions of miR-101 and whether circulating levels of miR-101 may contribute to the observed bone-anabolic properties of this microRNA.

Experimental procedures

MC3T3 cell culture and osteogenic differentiation

MC3T3 E1 sc4 murine calvarial osteoblasts⁶⁸ were purchased from American Type Culture Collection and maintained in α-minimal essential medium without ascorbic acid (Gibco) containing 10% fetal bovine serum (Atlanta Biologicals), 100 units/ml penicillin (Gibco), and 100 μg/ml streptomycin (Gibco) in cell culture incubators (37 °C and 5% CO₂). For experiments, cells were plated at 10,000 cells/cm² in maintenance medium. Osteogenic differentiation was induced the next day by the addition of 50 μg/ml ascorbic acid (Sigma) and 4 mM β-glycerol phosphate (Sigma). Alternatively, cells were transfected one day after plating and maintained in growth medium or differentiated in osteogenic medium as described in text.

Isolation of tissues for RNA assessment

Parietal and frontal bones (calvaria) were harvested from three 2–3 days old C57BL/6 Prrx1-Cre + female pups (i.e., #1, #2, and #3 are pup identification numbers)⁶⁹. For these studies, RNA from Prxx1-Cre + mice was used to reduce the number of animals as this RNA was previously generated for another study³⁷. To our knowledge, no studies to date have reporter a phenotype in Prrx1-Cre + , which alleviates concerns related to potential miRNA changes in Prxx1-Cre + relative to C57BL/6 wild type mice. The calvaria were then washed in cold phosphate buffered saline (PBS), incubated in collagenase digestion medium (αMEM, 2 mg/ml collagenase type II, and 0.005% trypsin) for 20 min at 37 °C, washed in PBS, snap-frozen in liquid nitrogen, and stored at − 80 °C until further processing^37,57. Tissues from eight-week-old mice were freshly harvested, snap-frozen in liquid nitrogen, and stored at − 80 °C until further processing.

Transfection of miRNA mimics

MC3T3 E1 sc4 cells were transfected with miRNA mimics as described^35,37,70. Briefly, cells were seeded in 6- or 12-well plates in maintenance medium (10,000 cells/cm²). The next day, control (Cy3 dye-labeled Pre-miRNA Negative Control, AM17120, Thermo Fisher) and miRNA mimics, miR-101a-3p (MC11414, Thermo Fisher) and miR-27b (MC10750, Thermo Fisher), were transfected using RNAiMAX as instructed by the manufacturer (Invitrogen). Cells were subsequently cultured as described in the text.

RNA isolation and RT-qPCR analysis

Total RNA was isolated using the Direct-zol™ RNA kit (Zymo Research). Before isolation, calvaria (2-to-3-day old mice) and other tissues (eight-week-old mice) were homogenized for 30 s in ice-cold QIAzol using the Ultra Turrax T25 tissue homogenizer (IKA). RNA was quantified using the NanoDrop 2000 spectrophotometer (Thermo Fischer Scientific).

For mRNA analysis, RNA was reverse transcribed into cDNA by the SuperScript III First-Strand Synthesis System (Invitrogen). Gene levels were assessed using real-time PCR using the QuantiTect SYBR Green PCR Kit (Qiagen) and the CFX384 Real-Time System machine (BioRad). Transcript levels were quantified using the 2^ΔΔCt method and normalized to the housekeeping gene Gapdh (set at 100). Primer pairs are shown in Suppl Table 3.

For miRNA quantification, miRNAs were reverse transcribed into cDNA using the Mir-X miRNA First-Strand Synthesis Kit as instructed (Takara). Similar to mRNA, miRNA levels were determined using QuantiTect SYBR Green PCR Kit and the CFX384 Real-Time System machine. miRNA quantification was assessed using a universal reverse primer provided in First-Strand Synthesis Kit (Takara) and miRNA specific forward primers listed in Suppl Table 3. As with mRNA, miRNA levels were quantified using the 2^ΔΔCt method and normalized to miR-103a-3p (set at 100)⁷¹.

Western blotting

Cell lysis and western blot analysis was assessed as previously described^{33,35,37,57,63}. Proteins were visualized using the ECL Prime detection kit (GE Healthcare). Primary antibodies used include Ezh2 (1:10,000; 5246, Cell Signaling), Actin (1:10,000; sc-1616; Santa Cruz), histone H3 (1:10,000; 05–928; Millipore), and H3K27me3 (1:5000; 17–622; Millipore). Uncropped and additional examples of western blots are shown in Suppl Fig. 3. The blots were cut prior to antibody hybridization. Maximal sizes of the final blots for each antibody are shown in the supplementary data. Where necessary, images were cropped and rotated to ensure alignment of bands in the final figures.

Alizarin red staining and quantification

Mineral deposition of differentiating MC3T3 cells was assessed by alizarin red staining as previously described^{35,37,57,63,72}. Briefly, cell cultures were fixed in 10% neutral buffered formalin and stained with 2% Alizarin Red (Sigma) to visualize calcium deposits. Alizarin red absorption was quantified by ImageJ software⁷³.

Microscopy

Cell viability and visual evidence for miRNA transfection (Cy3 dye-labeled Pre-miRNA Negative Control) was examined using an inverted fluorescent microscope (ZeissAxioVert.A1). Cell viability was assessed using a two-color fluorescence assay based on the simultaneous determination of live (calcein acetoxymethyl [AM]: green) and dead (ethidium homodimer-1: red) cells as suggested by the manufacturer (Molecular Probes)^74,75 and images obtained with 10 × magnification objective with the Texas red filter. Cells transfected with a Cy3-labeled miRNA negative control were imaged under bright-field and Texas red filter using the 20 × magnification objective to confirm the presence of the fluorescent dye within the transfected cells. All images were processed with the Zen software (2.3 SP1, Zeiss 2015).

Animal welfare

Mouse studies were performed according to recommendations provided by the National Institutes of Health and the Institute of Laboratory Animal Resources, National Research Council. The Mayo Clinic Institutional Animal Care and Use Committee approved all animal studies. Animals were housed in an accredited facility under a 12-h light/dark cycle and provided water and food ad libitum. Mice were fed either a normal (PicoLab Rodent Diet 20, LabDiet) or a doxycycline-enriched diet (Mod LabDiet® 5053, LabDiet). All studies were done in accordance with Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines⁷⁶.

miR-101a transgenic mice

An unpublished derivative of the mouse embryonic stem (ES) cell line KH2 which supports transgenic expression of mature miR-101a (Stock Number: M000006) was obtained from the National Cancer Institute Mouse Repository (Frederick National Laboratory for Cancer Research, Frederick, MD). The KH2 cell line contains a second-generation reverse tetracycline transactivator (rtTA-M2) that is expressed from the Rosa26 promoter^77,78. The parental KH2 cell line also contains a specific recombination site (‘ColA’) that permits rapid insertion of transgene expression cassettes using the Flp recombinase^77,78. The recombination site is located 0.5 kbp downstream of the 3′UTR sequences of the mouse Col1a1 gene in a chromosomal region that is permissive for transcriptional activation in different mammalian species^77,79. The KH2 cell line was subsequently modified for the systematic analysis of gene function by RNA interference in which any small RNA (shRNA or miRNA) that is incorporated within the body of the precursor for miR-30 can be induced by tetracycline (doxycycline)⁴⁷. The KH2-M000006 cell line used in this study contains a multi-model gene cassette (TRE-GFP-miR-30/101a) in which a tetracycline response element (TRE) supports expression of a mRNA encoding green fluorescent protein (GFP) mRNA and a 3′UTR that contains the precursor scaffold for miR-30 in which the sequences for the mature miR-30 were replaced by the sequences of the mature miR-101a. A diagram clarifying the molecular components of the model is provided as Suppl Fig. 1. The ES cells were injected into C57BL/6 mouse blastocysts to generate chimeric mice. These mice were then bred to obtain germline transmission. The following genotyping primers were used: Col1a1 locus: Forward—AATCATCCCAGGTGCACAGCATTGCGG, Reverse #1—CTTTGAGGGCTCATGAACCTCCCAGG, Reverse #2—ATCAAGGAAACCCTGGACTACTGCG; Rosa locus: Forward #1—AAAGTCGCTCTGAGTTGTTAT, Forward #2—GGAGCGGGAGAAATGGATATG, Reverse—GCGAAGAGTTTGTCCTCAACC. For all experiments, homozygous miR-101a and homozygous Rosa26-rtTA were bred with each other or C57BL/6 wild type mice to generate the three experimental mice used in these studies: Rosa26-rtTA heterozygous mice (R26, Rosa26^rtTA/+), mir-101a heterozygous mice (101a, Col1a1^mir-101a/+), and Rosa26-rtTA heterozygous + mir-101 heterozygous (R26/101a, Rosa26^rtTA/+: Col1a1^mir-101a/+).

For post-natal induction of mir-101a (R26/101a cohorts only), breeding pairs and experimental mice were maintained on normal diet. At three weeks of age (weaning), experimental mice were maintained on regular diet or placed on doxycycline-enriched diet. For some mice, the doxycycline diet was replaced with regular diet at six weeks.

For pre-natal induction, all breeding mice were placed on doxycycline-rich diet at least five days before combining male and female breeders. Thus, for experimental mice, which includes all three genotypes (R26, 101a, and R26/101a), doxycycline-rich diet was provided from inception to sacrifice via mother (e.g., blood stream and milk) or by consuming doxycycline rich diet^47,48,49.

μCT analysis

Bones were scanned using a 65 kV source, 0.5 mm Al filter, 0.7° rotation and two-image averaging with an isotropic voxel size of 9 μm using a SkyScan 1176 system (SkyScan)⁸⁰. The terminology and units used for µCT are those recommended by the American Society for Bone and Mineral Research (ASBMR)⁸¹.

Bone histomorphometry

Femur from 8-week-old mice were fixed in 10% neutral buffered formalin and embedded using previously established methods at the ICMH Histology and Histomorphometry Core⁸⁰. Sagittal sections of methyl methacrylate-embedded femora were obtained. Osteoclasts were quantified in TRAPase/Toluidine blue-stained and osteoblasts/osteocytes in von Kossa/McNeal-stained sections. Histomorphometric analysis was performed using OsteoMeasure high resolution digital video system (OsteoMetrics Inc.). The terminology and units used are those recommended by the ASBMR Histomorphometry Nomenclature Committee⁸².

High throughput RNA sequencing and bioinformatic analysis

Total RNA from differentiating MC3T3 cells (days 0, 6, 10, 17, and 24) and mouse calvaria was isolated as described above. To normalize biological variation, three biological samples were pooled (equal amounts of RNA) for each MC3T3 time point. MicroRNAs were sequenced as previously described in detail^71,83,84. The resulting data were deposited in the Gene Expression Omnibus (GEO) of the National Center for Biotechnology Information (GSE155390). Of note, #1, #2, #3 calvaria within this manuscript correspond to samples p64, p73, and p88, respectively, within the GEO dataset. miRNA expression data are expressed in counts per million (CPM). Hierarchical clustering was performed using Morpheus matrix visualization and analysis software after a Log2 adjustment was made for each miRNA (Broad Institute, Cambridge, MA). Venn Diagrams were generated using Venny 2.1 online tool (BioinfoGP).

Circulating bone markers

Terminal serum samples were collected at sacrifice and stored at -80C. Serum N-terminal propeptide of type I procollagen (P1NP) (catalog #AC-33F1, Immunodiagnostic Systems Inc.) and C-telopeptide fragments (CTX) (catalog #AC-06F1, Immunodiagnostic Systems Inc.,) were measured as suggested by the manufacturer and previously described^85,86.

Statistics

Data are shown as mean ± standard deviation and statistical analysis was performed with unpaired Students t-test or one-way analysis of variance (ANOVA) using Tukey’s multiple comparisons test in GraphPad Prism 9. When the overall ANOVA F-test was significant, subsequent pairwise comparisons were performed using ordinary one-way ANOVA for multiple comparisons. Significance is noted (*p < 0.05; **p < 0.01; ***p < 0.001, and ****p < 0.001).

Data availability

The data that support the findings of this study are available in Gene Expression Omnibus (GEO) database at https://www.ncbi.nlm.nih.gov/geo/, Accessions #GSE155390.

References

Montecino, M., Carrasco, M. E. & Nardocci, G. Epigenetic control of osteogenic lineage commitment. Front. Cell Dev. Biol. 8, 611197. https://doi.org/10.3389/fcell.2020.611197 (2020).
Article PubMed Google Scholar
Plotkin, L. I. & Bruzzaniti, A. Molecular signaling in bone cells: Regulation of cell differentiation and survival. Adv. Protein Chem. Struct. Biol. 116, 237–281. https://doi.org/10.1016/bs.apcsb.2019.01.002 (2019).
Article CAS PubMed PubMed Central Google Scholar
Stein, G. S., Lian, J. B., Stein, J. L., Van Wijnen, A. J. & Montecino, M. Transcriptional control of osteoblast growth and differentiation. Physiol. Rev. 76, 593–629. https://doi.org/10.1152/physrev.1996.76.2.593 (1996).
Article CAS PubMed Google Scholar
Garcia, J. & Delany, A. M. MicroRNAs regulating TGFβ and BMP signaling in the osteoblast lineage. Bone 143, 115791. https://doi.org/10.1016/j.bone.2020.115791 (2021).
Article CAS PubMed Google Scholar
van Wijnen, A. J. et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11, 72–82. https://doi.org/10.1007/s11914-013-0143-6 (2013).
Article PubMed PubMed Central Google Scholar
Tye, C. E. et al. Could lncRNAs be the missing links in control of mesenchymal stem cell differentiation?. J. Cell. Physiol. 230, 526–534. https://doi.org/10.1002/jcp.24834 (2015).
Article CAS PubMed PubMed Central Google Scholar
Karner, C. M. & Long, F. Wnt signaling and cellular metabolism in osteoblasts. Cell Mol. Life Sci. 74, 1649–1657. https://doi.org/10.1007/s00018-016-2425-5 (2017).
Article CAS PubMed Google Scholar
Plotkin, L. I. & Bellido, T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat. Rev. Endocrinol. 12, 593–605. https://doi.org/10.1038/nrendo.2016.71 (2016).
Article CAS PubMed PubMed Central Google Scholar
St-Arnaud, R. The direct role of vitamin D on bone homeostasis. Arch. Biochem. Biophys. 473, 225–230. https://doi.org/10.1016/j.abb.2008.03.038 (2008).
Article CAS PubMed Google Scholar
Gordon, J. A. R., Stein, J. L., Westendorf, J. J. & van Wijnen, A. J. Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease. Bone 81, 739–745. https://doi.org/10.1016/j.bone.2015.03.011 (2015).
Article CAS PubMed PubMed Central Google Scholar
Dudakovic, A. & van Wijnen, A. J. Epigenetic control of osteoblast differentiation by enhancer of zeste homolog 2 (EZH2). Curr. Mol. Biol. Rep. 3, 94–106. https://doi.org/10.1007/s40610-017-0064-8 (2017).
Article Google Scholar
van Wijnen, A. J. & Westendorf, J. J. Epigenetics as a new frontier in orthopedic regenerative medicine and oncology. J. Orthop. Res. 37, 1465–1474. https://doi.org/10.1002/jor.24305 (2019).
Article PubMed PubMed Central Google Scholar
Lian, J. B. et al. MicroRNA control of bone formation and homeostasis. Nat. Rev. Endocrinol. 8, 212–227. https://doi.org/10.1038/nrendo.2011.234 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Gaur, T. et al. Dicer inactivation in osteoprogenitor cells compromises fetal survival and bone formation, while excision in differentiated osteoblasts increases bone mass in the adult mouse. Dev. Biol. 340, 10–21. https://doi.org/10.1016/j.ydbio.2010.01.008 (2010).
Article CAS PubMed PubMed Central Google Scholar
Hrdlicka, H. C. et al. Inhibition of miR-29-3p isoforms via tough decoy suppresses osteoblast function in homeostasis but promotes intermittent parathyroid hormone-induced bone anabolism. Bone 143, 115779. https://doi.org/10.1016/j.bone.2020.115779 (2021).
Article CAS PubMed Google Scholar
Huang, J. et al. The microRNAs miR-204 and miR-211 maintain joint homeostasis and protect against osteoarthritis progression. Nat. Commun. 10, 2876. https://doi.org/10.1038/s41467-019-10753-5 (2019).
Article ADS CAS PubMed PubMed Central Google Scholar
Li, Z. et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc. Natl. Acad. Sci. USA 105, 13906–13911. https://doi.org/10.1073/pnas.0804438105 (2008).
Article ADS PubMed PubMed Central Google Scholar
Kapinas, K., Kessler, C. B. & Delany, A. M. miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling. J. Cell. Biochem. 108, 216–224. https://doi.org/10.1002/jcb.22243 (2009).
Article CAS PubMed PubMed Central Google Scholar
Huang, J., Zhao, L., Xing, L. & Chen, D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 28, 357–364. https://doi.org/10.1002/stem.288 (2010).
Article CAS PubMed Google Scholar
Arciszewska, L. K., Drake, D. & Craig, N. L. Transposon Tn7 cis-Acting sequences in transposition and transposition immunity. J. Mol. Biol. 207, 35–52. https://doi.org/10.1016/0022-2836(89)90439-7 (1989).
Article CAS PubMed Google Scholar
Zhang, Y. et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc. Natl. Acad. Sci. USA 108, 9863–9868. https://doi.org/10.1073/pnas.1018493108 (2011).
Article ADS PubMed PubMed Central Google Scholar
Hassan, M. Q. et al. A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc. Natl. Acad. Sci. USA 107, 19879–19884. https://doi.org/10.1073/pnas.1007698107 (2010).
Article ADS PubMed PubMed Central Google Scholar
Hassan, M. Q. et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 287, 42084–42092. https://doi.org/10.1074/jbc.M112.377515 (2012).
Article CAS PubMed PubMed Central Google Scholar
van der Deen, M. et al. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J. Biol. Chem. 288, 21307–21319. https://doi.org/10.1074/jbc.M112.445890 (2013).
Article CAS PubMed PubMed Central Google Scholar
Dole, N. S. et al. A single nucleotide polymorphism in osteonectin 3’ untranslated region regulates bone volume and is targeted by miR-433. J. Bone Miner. Res. 30, 723–732. https://doi.org/10.1002/jbmr.2378 (2015).
Article CAS PubMed Google Scholar
Garcia, J. et al. miR-433-3p suppresses bone formation and mRNAs critical for osteoblast function in mice. J. Bone Miner. Res. 36, 1808–1822. https://doi.org/10.1002/jbmr.4339 (2021).
Article CAS PubMed Google Scholar
Zhang, Y. et al. Control of mesenchymal lineage progression by microRNAs targeting skeletal gene regulators Trps1 and Runx2. J. Biol. Chem. 287, 21926–21935. https://doi.org/10.1074/jbc.M112.340398 (2012).
Article CAS PubMed PubMed Central Google Scholar
Taipaleenmäki, H., BjerreHokland, L., Chen, L., Kauppinen, S. & Kassem, M. Mechanisms in endocrinology: Micro-RNAs: targets for enhancing osteoblast differentiation and bone formation. Eur. J. Endocrinol. 166, 359–371. https://doi.org/10.1530/eje-11-0646 (2012).
Article PubMed Google Scholar
Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695–1699. https://doi.org/10.1126/science.1165395 (2008).
Article ADS CAS PubMed PubMed Central Google Scholar
Tzatsos, A. et al. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J. Biol. Chem. 286, 33061–33069. https://doi.org/10.1074/jbc.M111.257667 (2011).
Article CAS PubMed PubMed Central Google Scholar
Greussing, R. et al. Identification of microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts. BMC Genomics 14, 224. https://doi.org/10.1186/1471-2164-14-224 (2013).
Article PubMed PubMed Central Google Scholar
Wang, H. et al. MiR-101 targets the EZH2/Wnt/β-catenin the pathway to promote the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Sci. Rep. 6, 36988. https://doi.org/10.1038/srep36988 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Dudakovic, A. et al. Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2. J. Biol. Chem. 295, 7877–7893. https://doi.org/10.1074/jbc.RA119.011685 (2020).
Article CAS PubMed PubMed Central Google Scholar
Dudakovic, A. et al. Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice. J. Biol. Chem. 293, 12894–12907. https://doi.org/10.1074/jbc.RA118.002983 (2018).
Article CAS PubMed PubMed Central Google Scholar
Dudakovic, A. et al. Enhancer of zeste homolog 2 inhibition stimulates bone formation and mitigates bone loss caused by ovariectomy in skeletally mature mice. J. Biol. Chem. 291, 24594–24606. https://doi.org/10.1074/jbc.M116.740571 (2016).
Article CAS PubMed PubMed Central Google Scholar
Hemming, S. et al. EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling. FASEB J. 31, 1011–1027. https://doi.org/10.1096/fj.201600748R (2017).
Article CAS PubMed Google Scholar
Dudakovic, A. et al. Epigenetic control of skeletal development by the histone methyltransferase Ezh2. J. Biol. Chem. 290, 27604–27617. https://doi.org/10.1074/jbc.M115.672345 (2015).
Article CAS PubMed PubMed Central Google Scholar
Hemming, S. et al. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells 32, 802–815. https://doi.org/10.1002/stem.1573 (2014).
Article CAS PubMed Google Scholar
Hemming, S. et al. Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. Stem Cells Dev. 25, 909–921. https://doi.org/10.1089/scd.2015.0384 (2016).
Article CAS PubMed PubMed Central Google Scholar
Sen, B. et al. β-catenin preserves the stem state of murine bone marrow stromal cells through activation of EZH2. J. Bone Miner. Res. 35, 1149–1162. https://doi.org/10.1002/jbmr.3975 (2020).
Article CAS PubMed Google Scholar
Friedman, J. M. et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69, 2623–2629. https://doi.org/10.1158/0008-5472.CAN-08-3114 (2009).
Article CAS PubMed Google Scholar
Dudakovic, A. et al. Profiling of human epigenetic regulators using a semi-automated real-time qPCR platform validated by next generation sequencing. Gene 609, 28–37. https://doi.org/10.1016/j.gene.2017.01.019 (2017).
Article CAS PubMed PubMed Central Google Scholar
Zhang, K. et al. MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression. Oncol. Rep. 32, 2143–2149. https://doi.org/10.3892/or.2014.3459 (2014).
Article CAS PubMed Google Scholar
Wang, H. et al. MiR-101 targets the EZH2/Wnt/beta-catenin the pathway to promote the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Sci. Rep. 6, 36988 (2016).
Article ADS CAS Google Scholar
Wang, T. & Xu, Z. miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem. Biophys. Res. Commun. 402, 186–189. https://doi.org/10.1016/j.bbrc.2010.08.031 (2010).
Article CAS PubMed Google Scholar
Guo, D. et al. MiR-27a targets sFRP1 in hFOB cells to regulate proliferation, apoptosis and differentiation. PLoS ONE 9, e91354. https://doi.org/10.1371/journal.pone.0091354 (2014).
Article ADS CAS PubMed PubMed Central Google Scholar
Dow, L. E. et al. A pipeline for the generation of shRNA transgenic mice. Nat. Protoc. 7, 374–393. https://doi.org/10.1038/nprot.2011.446 (2012).
Article CAS PubMed PubMed Central Google Scholar
Becker, M. R., Choi, Y. S., Millar, S. E. & Udey, M. C. Wnt signaling influences the development of murine epidermal Langerhans cells. J. Invest. Dermatol. 131, 1861–1868. https://doi.org/10.1038/jid.2011.131 (2011).
Article CAS PubMed PubMed Central Google Scholar
Walters, B. J. & Zuo, J. A Sox10(rtTA/+) mouse line allows for inducible gene expression in the auditory and balance organs of the inner ear. J. Assoc. Res. Otolaryngol. 16, 331–345. https://doi.org/10.1007/s10162-015-0517-9 (2015).
Article PubMed PubMed Central Google Scholar
Golub, L. M. et al. Doxycycline effects on serum bone biomarkers in post-menopausal women. J. Dent. Res. 89, 644–649. https://doi.org/10.1177/0022034510363367 (2010).
Article CAS PubMed PubMed Central Google Scholar
Pytlik, M., Folwarczna, J. & Janiec, W. Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif. Tissue Int. 75, 225–230. https://doi.org/10.1007/s00223-004-0097-x (2004).
Article CAS PubMed Google Scholar
Walter, M. S. et al. Bioactive implant surface with electrochemically bound doxycycline promotes bone formation markers in vitro and in vivo. Dent. Mater. 30, 200–214. https://doi.org/10.1016/j.dental.2013.11.006 (2014).
Article CAS PubMed Google Scholar
Wang, C. Z. et al. MiR-101: A potential therapeutic target of cancers. Am. J. Transl. Res. 10, 3310–3321 (2018).
CAS PubMed PubMed Central Google Scholar
Wyngaarden, L. A., Delgado-Olguin, P., Su, I. H., Bruneau, B. G. & Hopyan, S. Ezh2 regulates anteroposterior axis specification and proximodistal axis elongation in the developing limb. Development 138, 3759–3767. https://doi.org/10.1242/dev.063180 (2011).
Article CAS PubMed Google Scholar
Schwarz, D. et al. Ezh2 is required for neural crest-derived cartilage and bone formation. Development 141, 867–877. https://doi.org/10.1242/dev.094342 (2014).
Article CAS PubMed Google Scholar
Lui, J. C. et al. EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy. Nat. Commun. 7, 13685. https://doi.org/10.1038/ncomms13685 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Camilleri, E. T. et al. Loss of histone methyltransferase Ezh2 stimulates an osteogenic transcriptional program in chondrocytes but does not affect cartilage development. J. Biol. Chem. 293, 19001–19011. https://doi.org/10.1074/jbc.RA118.003909 (2018).
Article CAS PubMed PubMed Central Google Scholar
Wei, Y. et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13, 87–94. https://doi.org/10.1038/ncb2139 (2011).
Article CAS PubMed Google Scholar
Huang, D. et al. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma. Oncol. Rep. 35, 1083–1090 (2016).
Article CAS Google Scholar
Chen, Y. H. et al. Enhancer of zeste homolog 2 and histone deacetylase 9c regulate age-dependent mesenchymal stem cell differentiation into osteoblasts and adipocytes. Stem Cells 34, 2183–2193 (2016).
Article CAS Google Scholar
Jing, H. et al. Suppression of EZH2 prevents the shift of osteoporotic MSC fate to adipocyte and enhances bone formation during osteoporosis. Mol. Ther. 24, 217–229. https://doi.org/10.1038/mt.2015.152 (2016).
Article CAS PubMed Google Scholar
Fang, C. et al. Cutting Edge: EZH2 promotes osteoclastogenesis by epigenetic silencing of the negative regulator IRF8. J. Immunol. 196, 4452–4456. https://doi.org/10.4049/jimmunol.1501466 (2016).
Article CAS PubMed Google Scholar
Dudakovic, A. et al. Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2. J. Biol. Chem. https://doi.org/10.1074/jbc.RA119.011685 (2020).
Article PubMed PubMed Central Google Scholar
Galvan, M. L. et al. Multiple pharmacological inhibitors targeting the epigenetic suppressor enhancer of zeste homolog 2 (Ezh2) accelerate osteoblast differentiation. Bone 150, 115993. https://doi.org/10.1016/j.bone.2021.115993 (2021).
Article CAS PubMed Google Scholar
Brase, J. C., Wuttig, D., Kuner, R. & Sültmann, H. Serum microRNAs as non-invasive biomarkers for cancer. Mol. Cancer 9, 306. https://doi.org/10.1186/1476-4598-9-306 (2010).
Article CAS PubMed PubMed Central Google Scholar
Etheridge, A., Lee, I., Hood, L., Galas, D. & Wang, K. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 717, 85–90. https://doi.org/10.1016/j.mrfmmm.2011.03.004 (2011).
Article CAS PubMed PubMed Central Google Scholar
Weiland, M., Gao, X. H., Zhou, L. & Mi, Q. S. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 9, 850–859. https://doi.org/10.4161/rna.20378 (2012).
Article CAS PubMed Google Scholar
Wang, D. et al. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14, 893–903. https://doi.org/10.1359/jbmr.1999.14.6.893 (1999).
Article CAS PubMed Google Scholar
Logan, M. et al. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 33, 77–80. https://doi.org/10.1002/gene.10092 (2002).
Article CAS PubMed Google Scholar
Paradise, C. R. et al. The epigenetic reader Brd4 is required for osteoblast differentiation. J. Cell. Physiol. 235, 5293–5304. https://doi.org/10.1002/jcp.29415 (2020).
Article CAS PubMed Google Scholar
Riester, S. M. et al. Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma. J. Orthop. Res. 35, 1137–1146. https://doi.org/10.1002/jor.23344 (2017).
Article CAS PubMed Google Scholar
Dudakovic, A. et al. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces akt phosphorylation. J. Biol. Chem. 288, 28783–28791. https://doi.org/10.1074/jbc.M113.489732 (2013).
Article CAS PubMed PubMed Central Google Scholar
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH image to imageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
Article CAS Google Scholar
Denbeigh, J. M. et al. Modernizing storage conditions for fresh osteochondral allografts by optimizing viability at physiologic temperatures and conditions. Cartilage https://doi.org/10.1177/1947603519888798 (2019).
Article PubMed PubMed Central Google Scholar
Kubrova, E. et al. Differences in cytotoxicity of lidocaine, ropivacaine, bupivacaine on the viability and metabolic activity of human adipose-derived mesenchymal stem cells. Am. J. Phys. Med. Rehabil. https://doi.org/10.1097/phm.0000000000001529 (2020).
Article PubMed Google Scholar
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412. https://doi.org/10.1371/journal.pbio.1000412 (2010).
Article CAS PubMed PubMed Central Google Scholar
Beard, C., Hochedlinger, K., Plath, K., Wutz, A. & Jaenisch, R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44, 23–28. https://doi.org/10.1002/gene.20180 (2006).
Article CAS PubMed Google Scholar
Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465–477. https://doi.org/10.1016/j.cell.2005.02.018 (2005).
Article CAS PubMed Google Scholar
McCreath, K. J. et al. Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 405, 1066–1069. https://doi.org/10.1038/35016604 (2000).
Article ADS CAS PubMed Google Scholar
Davis, H. M. et al. Cx43 overexpression in osteocytes prevents osteocyte apoptosis and preserves cortical bone quality in aging mice. JBMR Plus 2, 206–216. https://doi.org/10.1002/jbm4.10035 (2018).
Article CAS PubMed PubMed Central Google Scholar
Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468–1486. https://doi.org/10.1002/jbmr.141 (2010).
Article PubMed Google Scholar
Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J. Bone Miner. Res. 28, 2–17. https://doi.org/10.1002/jbmr.1805 (2013).
Article PubMed Google Scholar
Riester, S. M. et al. RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren’s disease. BMC Med. Genomics 8, 59. https://doi.org/10.1186/s12920-015-0135-8 (2015).
Article CAS PubMed PubMed Central Google Scholar
Morhayim, J. et al. Osteoblasts secrete miRNA-containing extracellular vesicles that enhance expansion of human umbilical cord blood cells. Sci. Rep. 6, 32034. https://doi.org/10.1038/srep32034 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Pacheco-Costa, R. et al. Defective cancellous bone structure and abnormal response to PTH in cortical bone of mice lacking Cx43 cytoplasmic C-terminus domain. Bone 81, 632–643. https://doi.org/10.1016/j.bone.2015.09.011 (2015).
Article CAS PubMed PubMed Central Google Scholar
Pacheco-Costa, R. et al. Reversal of loss of bone mass in old mice treated with mefloquine. Bone 114, 22–31. https://doi.org/10.1016/j.bone.2018.06.002 (2018).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank current and past members of our laboratories, including Scott Riester, Margarita Carrasco Jeldres, Leila Bagheri, and Eric Lewallen for sharing ideas and reagents. We acknowledge the support of Asha Nair from the Bioinformatics Core and Medical Genome Facility at Mayo Clinic. This work was supported, in whole or in part, by National Institutes of Health Grants R01 AR049069 (AvW) and F32 AR066508 (AD) as well as a Career Development Award in Orthopedics Research (AD). We also appreciate the generous philanthropic support of William H. and Karen J. Eby, and the charitable foundation in their names.

Author information

Authors and Affiliations

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA
Amel Dudakovic, Sofia Jerez, Janet M. Denbeigh, Martina Gluscevic, Pengfei Zan, Dana L. Begun, Emily T. Camilleri, Oksana Pichurin, Farzaneh Khani, Roman Thaler & Jennifer J. Westendorf
Department of Biochemistry & Molecular Biology, Mayo Clinic, Rochester, MN, USA
Amel Dudakovic & Jennifer J. Westendorf
Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, USA
Padmini J. Deosthale & Lilian I. Plotkin
Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA
Christopher R. Paradise
Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA
Christopher R. Paradise & Martina Gluscevic
Department of Orthopedic Surgery, School of Medicine, Second Affiliated Hospital of Zhejiang University, Hangzhou, China
Pengfei Zan
Department of Orthopedic Surgery, School of Medicine, Shanghai Tenth People’s Hospital Affiliated to Tongji University, Shanghai, China
Pengfei Zan
Department of Biochemistry, University of Vermont, Burlington, VT, USA
Jane B. Lian, Gary S. Stein & Andre J. van Wijnen
Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA
Lilian I. Plotkin
Richard L Roudebush VA Medical Center, Indianapolis, IN, USA
Lilian I. Plotkin

Authors

Amel Dudakovic
View author publications
You can also search for this author in PubMed Google Scholar
Sofia Jerez
View author publications
You can also search for this author in PubMed Google Scholar
Padmini J. Deosthale
View author publications
You can also search for this author in PubMed Google Scholar
Janet M. Denbeigh
View author publications
You can also search for this author in PubMed Google Scholar
Christopher R. Paradise
View author publications
You can also search for this author in PubMed Google Scholar
Martina Gluscevic
View author publications
You can also search for this author in PubMed Google Scholar
Pengfei Zan
View author publications
You can also search for this author in PubMed Google Scholar
Dana L. Begun
View author publications
You can also search for this author in PubMed Google Scholar
Emily T. Camilleri
View author publications
You can also search for this author in PubMed Google Scholar
Oksana Pichurin
View author publications
You can also search for this author in PubMed Google Scholar
Farzaneh Khani
View author publications
You can also search for this author in PubMed Google Scholar
Roman Thaler
View author publications
You can also search for this author in PubMed Google Scholar
Jane B. Lian
View author publications
You can also search for this author in PubMed Google Scholar
Gary S. Stein
View author publications
You can also search for this author in PubMed Google Scholar
Jennifer J. Westendorf
View author publications
You can also search for this author in PubMed Google Scholar
Lilian I. Plotkin
View author publications
You can also search for this author in PubMed Google Scholar
Andre J. van Wijnen
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

A.D. and A.J.v.W. designed the study. A.D., S.J., P.J.D., J.M.D., C.R.P., M.G., P.Z., D.L.B., E.T.C., O.P., F.K., R.T., and L.I.P. performed the biological experiments. A.D., J.B.L., G.S.S., J.J.W., L.I.P., and A.J.v.W. provided interpretation of results and guidance of studies. A.D., J.J.W., L.I.P. and A.J.v.W. wrote the paper with comments from all authors.

Corresponding authors

Correspondence to Amel Dudakovic, Lilian I. Plotkin or Andre J. van Wijnen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Supplementary Figure 1.

Supplementary Figure 2.

Supplementary Figure 3.

Supplementary Table 1.

Supplementary Table 2.

Supplementary Table 3.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Dudakovic, A., Jerez, S., Deosthale, P.J. et al. MicroRNA-101a enhances trabecular bone accrual in male mice. Sci Rep 12, 13361 (2022). https://doi.org/10.1038/s41598-022-17579-0

Download citation

Received: 02 March 2022
Accepted: 27 July 2022
Published: 03 August 2022
DOI: https://doi.org/10.1038/s41598-022-17579-0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.